Bio-Sourcing

Executive Summary

Bio-Sourcing is a Belgian biotechnology company that has developed an innovative platform for producing monoclonal antibodies in the milk of genetically engineered goats. Founded in 2014, the company aims to address the high cost and limited accessibility of biotherapeutics by replacing traditional stainless-steel bioreactors with a scalable, animal-based 'bio-tank' system. This approach promises to lower production costs, reduce environmental footprint, and enable rapid scale-up to meet global demand. Bio-Sourcing's platform leverages the natural protein synthesis machinery of goats to produce complex antibodies with high yield and quality, potentially disrupting the conventional manufacturing paradigm. The company's business model revolves around co-development and co-ownership partnerships with pharmaceutical companies and governments, allowing it to share risks and rewards while accelerating the path to market. By targeting both generic biosimilars and novel antibody candidates, Bio-Sourcing offers a flexible and sustainable production alternative. With an experienced team in Ghent and growing interest in alternative biologics manufacturing, the company is well-positioned to capture value in the expanding antibody market. However, regulatory acceptance and scaling challenges remain key hurdles. Overall, Bio-Sourcing represents a compelling, if early-stage, opportunity in the biologics production space.

Upcoming Catalysts (preview)

• Q3 2026First Co-Development Partnership with a Major Pharma70% success
• Q4 2025Completion of Preclinical Proof-of-Concept for Lead Antibody80% success
• TBDSeries B Funding Round to Scale Production65% success